温馨提示:本文仅基于疾病科普分享,不能代替医院诊疗。意见仅供参考,具体治疗方式请遵医嘱。
封面图片:稿定设计
责任编辑:觅健科普君
参考资料:
[1] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.
[2]中国抗癌协会肝癌专业委员会转化治疗协作组.肝癌转化治疗中国专家共识(2021版)[J].中国实用外科杂志,2021,41(6):618-632.
[3]Finn RS,Qin S,Ikeda M,et al.IMbrave150: Updated overall survival(OS)data from a global,randomized,open- label phase III study of atezolizumab(atezo) + bevacizumab(bev)versus sorafenib(sor)in patients(pts)with unresectable hepatocellular carcinoma(HCC)[J].J Clin Oncol,2021,39(suppl 3):267-267.
[4]Kudo M,Ikeda M,Motomura K,et al.A phase Ib study of lenva-tinib(LEN)plus nivolumab(NIV)in patients(pts)with unresect-able hepatocellular carcinoma(uHCC): Study 117[J].J Clin On-col,2020,38(suppl 4):513.
[5]Finn RS,Ikeda M,Zhu AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellu-lar carcinoma[J].J Clin Oncol,2020,38(26):2960-2970.
[6]Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): A phase II trial,2022ESMO,(711P).
[7]Song Y, Zhou K, Jin C et al A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL). J Clin Oncol ,2021,39:7529.
[8]Chen X, Wang W, Zou Q et al.A phase II study of the anti-programmed cell death-1 (pd-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (npc) who had progressed after two or more lines of chemotherapy. J Immunother Cancer ,2020, 8:A481.
[9]Han B, Chen J, Wang Z et al. Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous nonsmall-cell lung cancer. J Clin Oncol,2021, 39(15):e21072.
[10]Han B, Li K, Wang Q, et al. Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC[J]. 2017.
[11]Cheng Y, Wang Q, Li K, et al. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)[J]. Annals of Oncology, 2019, 30:
[12]Chi Y, Yao Y, Wang S, et al. Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial[J]. 2018
[13] Shun Chang Jiao, Li Bai, et al. Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated overall survival results from a phase Ib/II study[J]. Journal of Clinical Oncology 2021 39:3_suppl, 306-306.